{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:31:53Z","timestamp":1786422713592,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease is a cardiomyopathy with multisystemic manifestations that is easily to be misdiagnosed as another type of cardiomyopathy. Fabry cardiomyopathy may present with left ventricular outflow tract obstruction (LVOTO), mimicking obstructive hypertrophic cardiomyopathy (oHCM). We present three cases of genetically confirmed Fabry disease that were initially misdiagnosed as oHCM, highlighting the importance of early recognition and tailored management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed Fabry disease screening on patients diagnosed with oHCM and ultimately identified three individuals who have received oHCM-specific treatments including mavacamten and alcohol septal ablation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three patients (2 females, 1 male; aged 48\u201366 years) who were initially diagnosed with and managed for oHCM based on septal hypertrophy and elevated left ventricular outflow tract gradients (LVOTG), was found to have GLA gene mutations. Enzyme replacement therapy with agalsidase alfa in two patients was associated with stabilization or improvement in wall thickness and LVOTO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fabry cardiomyopathy can present with a hypertrophic phenotype and significant LVOTO, and is often misdiagnosed as oHCM. This further underscores the importance of genetic testing in the etiological diagnosis of hypertrophic cardiomyopathies. Enzyme replacement therapy may ameliorate obstruction, while mavacamten and septal reduction therapies require caution without definitive genotype-phenotype correlation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1901732","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:20:10Z","timestamp":1786422010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Fabry cardiomyopathy presenting as hypertrophic phenotype with left ventricular outflow tract obstruction: a case series"],"prefix":"10.3389","volume":"13","author":[{"given":"Felycia Fernanda","family":"Hosyanto","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pcad.2025.08.003","article-title":"Fabry disease cardiomyopathy: a state-of-the-art review","volume":"92","author":"Pande","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.amjcard.2021.03.042","article-title":"Usefulness of alcohol septal ablation in the left ventricular outflow tract obstruction in Fabry disease cardiomyopathy","volume":"150","author":"Zem\u00e1nek","year":"2021","journal-title":"Am J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.amjcard.2020.07.020","article-title":"Ventricular septal myectomy for the treatment of left ventricular outflow tract obstruction due to Fabry disease","volume":"132","author":"Raju","year":"2020","journal-title":"Am J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.athoracsur.2012.05.087","article-title":"Outcome of septal myectomy in patients with Fabry's Disease","volume":"95","author":"Kunkala","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jamacardio.2017.2353","article-title":"Intraoperative diagnosis of anderson-fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy","volume":"2","author":"Cecchi","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1666","DOI":"10.1002\/mgg3.1666","article-title":"The benefits and challenges of family genetic testing in rare genetic diseases\u2014lessons from Fabry disease","volume":"9","author":"Germain","year":"2021","journal-title":"Mol Genet Genomic Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"220198","DOI":"10.1098\/rsob.220198","article-title":"NDUFS3 knockout cancer cells and molecular docking reveal specificity and mode of action of anti-cancer respiratory complex I inhibitors","volume":"12","author":"Kurelac","year":"2022","journal-title":"Open Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1651-2227.2005.tb02119.x","article-title":"Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr Suppl."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.2174\/1381612826666200317142412","article-title":"Treatment of anderson-fabry disease","volume":"26","author":"Simonetta","year":"2020","journal-title":"CPD"},{"key":"B16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/diagnostics12112652","article-title":"Cardiac magnetic resonance in fabry disease: morphological, functional, and tissue features","volume":"12","author":"Aquaro","year":"2022","journal-title":"Diagnostics (Basel)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/RRCC.S553380","article-title":"GLA and MYH7 double mutation causing fabry disease with familial hypertrophic cardiomyopathy: a case report","volume":"17","author":"Zheng","year":"2026","journal-title":"RRCC"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1554.e1","DOI":"10.1016\/j.cjca.2020.04.008","article-title":"A pathogenic galactosidase a mutation coexisting with an MYBPC3 mutation in a female patient with hypertrophic cardiomyopathy","volume":"36","author":"Vitale","year":"2020","journal-title":"Canadian J Cardio."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1901732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:20:10Z","timestamp":1786422010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1901732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2026.1901732"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1901732","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1901732"}}